Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172240 | 0.87 | ACHE (0.44) | GABRA1GABRB2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14484993 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3953513 | 0.85 | EED (0.40) | GABRA1GABRB2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23841325 | 0.85 | GABRA1 (0.45) | GABRA1GABRB2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6883141 | 0.85 | TAAR1 (0.55) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL14227249 | 0.82 | SLC6A2 (0.50) | GABRA1GABRB2SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL12775591 | 0.82 | SLC6A2 (0.50) | SMN1; SMN2L3MBTL1SLC6A2SLC6A4MAOA | |
| SCHEMBL2422907 | 0.81 | GAA (0.38) | GABRA1GABRB2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18400702 | 0.81 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL14478256 | 0.81 | SLC6A2 (0.52) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230272197-A1 | BIMODAL POLYETHYLENE COPOLYMERS | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2023-08-31 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-7446125-B2 | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2008-11-04 | — | — | US | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| WO-2008072053-A2 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008025694-A1 | INHIBITORS FOR GLYT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-4501746-A | HERBICIDES; PLANT GROWTH REGULATORS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | GABRA1 1882/4885GABRB2 2786/4885KDM4E 3806/4885 |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | GABRA1 3710/4885GABRB2 3185/4885KDM4E 2994/4885 |
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | GABRA1 163/4885GABRB2 184/4885KDM4E 1690/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | GABRA1 4307/4885GABRB2 4433/4885KDM4E 3971/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | GABRA1 4307/4885GABRB2 4433/4885KDM4E 3971/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | GABRA1 4719/4885GABRB2 4546/4885KDM4E 167/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GABRA1 611/4885GABRB2 729/4885KDM4E 1846/4885 |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | GABRA1 113/4885GABRB2 128/4885KDM4E 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.